Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia

The aim of this study is to assess longer term safety and effectiveness of Dysport®.

Inclusion Criteria:

• Subjects enrolled in the Y-47-52120-051 study, who have completed all study visits up to Week 12, or up to Week 4 in the event of an early withdrawal
• Returned to pre-treatment status as judged by the Investigator

Exclusion Criteria:

• Pure anterocollis or pure retrocollis
• Known antibodies to botulinum toxin type A
• Requirement for botulinum toxin injections to site(s) other than the neck and unable to avoid such treatment for the duration of the study
• Known significant underlying swallowing or respiratory abnormality which might be exacerbated by botulinum toxin treatment